August 09, 2018 1

Enabling InnovationBuilding a Market Leader in Molecular Biology

August 2018 – Half Year Results 2018 & Outlook 2018

August 09, 2018 2

Today on the Call

Heikki Lanckriet, PhD – CEO/CSO

David Roth – CFO

August 09, 2018 3

Disclaimer

This document is intended for prospective investors, partners and media audiences and no statements made here should be considered as claims for the success of our products, which are currently in the development phase. This document also may contain projections and/or estimates about and descriptions of plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements. These statements are forward-looking and are subject to risks and uncertainties, many of which are beyond our control and are not to be regarded as guarantees of future events.

Actual results could differ materially depending on a number of factors, including the timing and effects of regulatory actions, the results of product tests, the Company's relative success developing and gaining market acceptance for any new products, and the effectiveness of patent protection.

There can be no guarantee regarding the results of the product tests or other on going studies with our products. There can be no guarantee that our products in development will be approved for marketing in a timely manner, if at all.

The Company disclaims any intent or obligation to update these forward-looking statements or the factors that may affect the Company's future results, performance or achievements, even if new information becomes available in the future.

August 09, 2018 4

Agenda

• Group Overview

• Vision & Strategy

• Operational Review H1 2018

• Financial Review H1 2018 and Outlook FY 2018

August 09, 2018 5

SYGNIS AG Renamed to Expedeon AG

• Completion of the change of name to Expedeon AG

• Entry in the Mannheim commercial register on 6 August 2018

• Expedeon continues to be listed on the Regulated Market of the Frankfurt Stock Exchange

• ISIN and German securities identification code remain unchanged (DE000A1RFM03)

• Ticker symbol has been changed to EXN

• Name change reflects the new structure and positioning of the enlarged Company and the approval of the Annual General Meeting held on 5 July 2018

August 09, 2018 6

Group Overview

• ~110 staff across six countries

• Global sales team, business development and marketing in Cambridge/UK

• US-focused sales team in San Diego

• R&D centered in Madrid and Cambridge

• Manufacturing in San Diego, Cambridge, Madrid and Adelaide

Sales

Heidel-berg

CorporateMadrid

R&D,Manufacturing

San Diego

Manufacturing, Sales

Cam-bridge Manufacturing,

Sales, R&D

Singa-pore

Sales

Ade-laide

Manufacturing, Sales, R&D

August 09, 2018 7

Our Products

TruePrimeQualiPhiMutants

SunScript

SensiPhi Double Switch

Amintra Affinity Resins

VersaWave

Proteoloc

Nvoy Technology

BCA

Nvoy Solubility

Western Blot

PolyMACBradford

AnalysisSample

EnrichmentPurification Quantitation Analysis

Instant Blue

RunBlue

GelFree 8100

Fractionation

ImmunoreagentsProteomicsGenomics

Analysis

Lightning-Link

Thunder-Link

BioconjugationAssays and reagents

FlexLISA

Nanoparticles labeling kits

Imm-Link kits

Ready madeconjugates

Purification

AffinityResins

AbPure

AbSelect

Western Blot

ElectronMicroscopy

Flow cytometry

FRET

Check & Go

Lateral flowCovCheck

ATP/GTP resins

ATP/GTPase

August 09, 2018 8

Key Technologies

Next Generation Sequencing

Liquid Biopsy, Oncology

Point-of-care / Rapid

Diagnostics

Proteomics, Personalised

Medicine

TruePrime™ Whole Genome Amplification

Lightning-Link®

Biomarker Detection/Quantitation

ColloidalGold

RunBlue™Biomarker Analysis

CaptSure™Biomarker Capture

August 09, 2018 9

Agenda

• Group Overview

• Vision & Strategy

• Operational Review H1 2018

• Financial Review H1 2018 and Outlook FY 2018

August 09, 2018 10

Corporate Vision

• Become a market leading innovator enabling:

- Advances in medical science

- Advances in patient care

• By developing products and services built on proprietary technology, which:

- Accelerate and simplify bio-molecular research

- Enable biopharmaceutical and diagnostic products and solutions

August 09, 2018 11

Strategy

• Innovation driving organic growthDevelop and sell clever and easy to use products and services that our customers want to use

• Scale driving profitabilityAcquire complementary technologies which further enhance

- Growth

- Economies of scale and

- Profitability

• Maximise shareholder valueCreate a market leader with high profitability through innovation and scale

August 09, 2018 12

Strategy: Grow, Buy & Build

● Efficiently expand portfolio, technology and sales channels for all key markets

● Leverage growth by infrastructure synergies

● Accelerate growth to establish a leadership position

● Acquisition of profitable, debt-free, innovative companies with high growth rates

● New products, services & technologies for genomics, proteomics and immunology research

● Nurture high value clinical applications

Buy

Grow

Build

August 09, 2018 13

Sales and Marketing Model

● Intelligence driven direct mail

● Brochures

● Rich content website

● SEO, Web shop

● Local exhibitions

● Internationalevents

● Twitter

● Facebook

● Product video feeds

• Worldwide

• Higher margins

• Customer feedback

• End-user database marketing

Direct Marketing

E-Commerce

Conferences Social Media

Direct Sales (40%)

Distribution (40%)

OEM and Supply

Agreement (15%)

Licensing(5%)

• Local distributors: Europe, Far East

• Global distributors

• Wider reach

• Global reach

• Lower margins

• Economies of scale

• High margin

• Small proportion of the value chain

Marketing Approach

August 09, 2018 14

Agenda

• Group Overview

• Vision & Strategy

• Operational Review H1 2018

• Financial Review H1 2018 and Outlook FY 2018

August 09, 2018 15

Year-to-Date 2018: Milestones

• Extended OEM agreement with leading global research tools supplier

- Provide customers with improved access to research tools

- Worldwide sales and distribution channels

• Successful integration of products and services

- Expedeon Holdings, Innova Biosciences and C.B.S. Scientific fully integrated

- All products and companies operate under one brand name, Expedeon

• Completion of Sales and Marketing team restructuring

- Support continued strong revenue growth

- Cost leverage

• Acquisition of TGR Biosciences

- Australian research reagents company with complementary portfolio

Expedeon

SYGNIS

Innova Biosciences

C.B.S. Scientific

TGR Biosciences

August 09, 2018 16

TGR Biosciences: Commercial & Financial

Blue Chip OEM customers Technology included in market leading pharma platform

Established Production and R&D12 full time staff

Strong technology overlap

Strong GrowthRevenues € ~3.6 million (2017e)Annual growth: ~20% (3yr)

ProfitableEBIT: € ~1.3 million (2017e)

Debt-free

August 09, 2018 17

Agenda

• Group Overview

• Vision & Strategy

• Operational Review H1 2018

• Financial Review H1 2018 and Outlook FY 2018

August 09, 2018 18

Year-to-Date 2018: Financial Highlights

• Revenues rapidly growing

- €5.6 million (H1 2017: €3.0 million)

- Increase of 89% compared with H1 2017

• €6.2 million raised in a private placement and debt issues

- Funds used to acquire Australian research reagents company TGR Biosciences in May 2018

• H1 EBITDA positive

- Overall positive EBITDA 2018 expected

• Financial results fully within projection of guidance 2018

- Guidance raised for 2018 to €13-14 million (previous revenue guidance: €11-12 million)

- Increase of 67% against 2017 reported revenues

August 09, 2018 19

Consolidated Statement of Comprehensive IncomeIn € million Three Months ended

30 June 2018Three Months ended

30 June 2017Six Months ended 30

June 2018Six Months ended 30

June 2017

Revenues 3.3 1.6 5.6 3.0

Costs of goods sold (0.9) (0.6) (1.5) (1.5)

Expenses

Sales (0.8) (0.3) (1.3) (0.6)

Administration (2.0) (1.4) (3.2) (2.7)

Research & development (0.3) (0.2) (0.5) (0.3)

Other operating income/(expenses) 0.03 0.04 0.02 (0.03)

Total operating expenses (3.9) (2.5) (6.6) (5.2)

Results of operating activities (0.6) (0.9) (1.0) (2.2)

Earnings before taxes (0.7) (0.9) (1.1) (2.2)

Net profit/(loss) for the period (0.6) (0.8) (0.9) (2.0)

August 09, 2018 20

Financials H1 2018: Composition of Operating Income and Expensesin € thousand Effect of Non-cash Charges

six Months to 30 June

2018 2017

Reported EBIT (1,011) (2,188)

Amortisation and depreciation 1,034 541

EBITDA 23 (1,647)

Other non-cash charges:

PPA Fair value charge for inventory acquired and now sold 17 658

Equity settled share compensation 124 0

141 658

EBITDA Adjusted 164 (989)

August 09, 2018 21

Balance Sheet as of June 30, 2018Selected balance sheet data (in € million) 2018 (Jun 30) 2017 (Dec 31)

Non-current assets 53.8 44.0

thereof goodwill 34.8 30.7

thereof other intangible assets 16.6 11.3

Current assets 6.9 6.0

thereof cash and cash equivalents 1.1 2.0

Total assets 60.7 50.0

Shareholders’ equity 43.8 40.0

Non-current financial liabilities 9.6 5.3

thereof financial liabilities 6.7 3.9

Current liabilities 7.3 4.6

Total equity and liabilities 60.7 50.0

August 09, 2018 22

Outlook 2018

Continue to expand and consolidate the product portfolio; generate ongoing growth through strong organic products sales and acquisition

Outlook on financials

Revenues: 2018: €13-14 millionOngoing upside potential in 2019

EBITDA: EBITDA positive

Cash flow: Become cash flow positive during 2018

The goal of the Company is to become increasingly profitable through a combination of organic growth and growth by acquisitions.

August 09, 2018 23

Expedeon Current Stock Information (as of 9 August 2018)

Ticker symbol: EXN (Xetra)

ISIN: DE000A1RFM03

WKN: A1RFM0

Issued shares: 50,658,270

Listing: Germany: Deutsche Börse (Prime Standard)(Major Stock Exchanges)

Free float: ~ 81%

Key shareholders (>3%):Deutsche Balaton: 6.3%; Alpenfels Family Trust: 3.9%;

Fernandez Trust: 5.2%; Dr. Heikki Lanckriet: 3.1%

Market cap: € ~70 million

Analysts: GBC AG (Cosmin Filker; BUY: €3.30)

August 09, 2018 24

Thank You for Your Attention

For more information, please contact:

www.expedeon.comwww.investors.expedeon.com

Dr. Heikki Lanckriet, CEO/CSO

Email: heikki.lanckriet@expedeon.com

Phone: +44 1223 873364

Raimund Gabriel

Email: expedeon@mc-services.eu

Phone: +49 89 210 228 0

MC Services AG

Expedeon AG